Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer

Cytokine

Volumn 53, Issue 3, 2011, Pages 370-375

  Koukourakis, Michael I ^a   Limberis, Vassilios ^a   Tentes, Ioannis ^a   Kontomanolis, Emmanuel ^a   Kortsaris, Alexandros ^a   Sivridis, Efthimios ^a   Giatromanolaki, Alexandra ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Breast; Endometrium; Receptors; VEGF

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FIBROCYSTIC BREAST DISEASE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHOSPHORYLATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79251608534     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.12.007     Document Type: Article

References (38)

1. Vincenti V., Cassano C., Rocchi M., Persico G. Assignment of the vascular endothelial growth factor gene to the human chromosome 6p21.3. Circulation 1996, 93:1493-1495.
2. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
3. Itaya H., Imaizumi T., Yoshida H., Koyama M., Suzuki S., Satoh K. Expression of vascular endothelial growth factor in human monocyte/macrophages stimulated with lipopolysaccharide. Thromb Haemost 2001, 85:171-176.
4. Kirito K., Fox N., Komatsu N., Kaushansky K. Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1alpha. Blood 2005, 105:4258-4263.
5. Stewart M., Turley H., Cook N., Pezzella F., Pillai G., Ogilvie D., et al. The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology 2003, 43:33-39.
6. Fox S.B., Turley H., Cheale M., Blázquez C., Roberts H., James N., et al. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol 2004, 202:313-320.
7. Masood R., Cai J., Zheng T., Smith D.L., Hinton D.R., Gill P.S. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001, 98:1904-1913.
8. Price D.J., Miralem T., Jiang S., Steinberg R., Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001, 12:129-135.
9. Jackson M.W., Roberts J.S., Heckford S.E., Ricciardelli C., Stahl J., Choong C., et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002, 62:854-859.
10. Giatromanolaki A, Koukourakis MI, Pezzella F, Sivridis E, Turley H, Harris AL, Gatter KC. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 2008 May 7. [Epub ahead of print].
11. Giatromanolaki A., Koukourakis M.I., Sivridis E., Chlouverakis G., Vourvouhaki E., Turley H., et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007, 37:878-886.
12. Giatromanolaki A., Koukourakis M.I., Turley H., Sivridis E., Harris A.L., Gatter K.C. Tumour and Angiogenesis Research Group. Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Mod Pathol 2006, 19:701-707.
13. Nishida N., Yano H., Komai K., Nishida T., Kamura T., Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004, 101:1364-1374.
14. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997, 57:963-969.
15. Dirix L.Y., Vermeulen P.B., Pawinski A., Prové A., Benoy I., De Pooter C., et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997, 76:238-243.
16. Ding S., Lin S., Dong X., Yang X., Qu H., Huang S., et al. Potential prognostic value of circulating levels of vascular endothelial growthfactor-A in patients with gastric cancer. In Vivo 2005, 19:793-795.
17. Kapsoritakis A., Sfiridaki A., Maltezos E., Simopoulos K., Giatromanolaki A., Sivridis E., et al. Vascular endothelial growth factor in inflammatory bowel disease. Int J Colorectal Dis 2003, 18:418-422.
18. Jaroszewicz J., Januszkiewicz M., Flisiak R., Rogalska M., Kalinowska A., Wierzbicka I. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. Cytokine 2008, 44:14-17.
19. Maloney J.P., Silliman C.C., Ambruso D.R., Wang J., Tuder R.M., Voelkel N.F. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998, 275:H1054-H1061.
20. Wartiovaara U., Salven P., Mikkola H., Lassila R., Kaukonen J., Joukov V., et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998, 80:171-175.
21. Amirkhosravi A., Amaya M., Siddiqui F., Biggerstaff J.P., Meyer T.V., Francis J.L. Blockade of GPIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets 1999, 10:285-292.
22. Möhle R., Green D., Moore M.A.S., Nachman R.L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997, 94:663-668.
23. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
24. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
25. Salven P., Perhoniemi V., Tykkä H., Mäenpää H., Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 1999, 53:161-166.
26. Li L., Wang L., Zhang W., Tang B., Zhang J., Song H., et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 2004, 24:1973-1979.
27. Shaarawy M., El-Sharkawy S.A. Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer. Acta Oncol 2001, 40:513-518.
28. Lantzsch T., Hefler L., Krause U., Kehl A., Goepel C., Koelbl H., et al. The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer. Anticancer Res 2002, 22:1925-1928.
29. Heer K., Kumar H., Read J.R., Fox J.N., Monson J.R., Kerin M.J. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 2001, 7:3491-3494.
30. Gornall R.J., Anthony F.W., Coombes E.J., Hogston P., Woolas R.P. Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement. Int J Gynecol Cancer 2001, 11:164-166.
31. Erdem O., Erdem M., Erdem A., Memis L., Akyol G. Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma. Int J Gynecol Cancer 2007, 17:1327-1332.
32. Kuijper A., van der Groep P., van der Wall E., van Diest P.J. Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast. Breast Cancer Res 2005, 7:808-818.
33. Kumar H., Heer K., Duthie G.S., Monson J.R. Kinetics of postoperative serum vascular endothelial growth factor (VEGF) - can it be used to predict curative resections in colorectal cancer?. Anticancer Res 2002, 22:3717-3722.
34. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100; 2: 270-278.
35. Oehler M.K., Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 2000, 20:5109-5112.
36. Lin P., Sankar S., Shan S., Dewhirst M.W., Polverini P.J., Quinn T.Q., et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998, 9:49-58.
37. Millauer B., Longhi M.P., Plate K.H., Shawver L.K., Risau W., Ullrich A., et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996, 56:1615-1620.
38. Giatromanolaki A., Sivridis E., Brekken R., Thorpe P.E., Anastasiadis P., Gatter K.C., Koukourakis M.I., et al. Tumour and Angiogenesis Research Group. The angiogenic " vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 2001, 92:2569-2577.